Expert: Selective covalent inhibitor of Bruton's tyrosine kinase that disrupts B-cell receptor signaling critical for CLL and MCL survival.

Everyday: Blocks a protein that B-cell cancers need to survive and grow.

Targets: ["BTK"]

Remibrutinib - Hidradenitis Suppurativa - Ph3 - Topline H2 2026

Remibrutinib - CIndU - Ph3 - Topline H2 2026

Highly selective covalent BTK inhibitor for chronic spontaneous urticaria. Designed to minimize off-target kinase inhibition; targets B-cell and mast cell signaling in refractory urticaria.